Every earnings call for TORNTPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
TORNTPHARM · 6 transcripts · Healthcare · latest Q4 FY26Torrent Pharmaceuticals Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Consolidated Revenue ₹4,197 cr (+42% YoY); Operating EBITDA ₹1,356 cr (+41% YoY); Operating EBITDA Margin 32.3%. Consolidated revenue for Q4 FY26 was INR 4,197 crores, up 42% YoY.
Read full transcript & analysisRevenue ₹3,303 cr (+18% YoY); Operating EBITDA ₹1,088 cr (+19% YoY); EBITDA Margin 32.9%. Revenue reached ₹3,303 crores, representing an 18% YoY growth.
Read full transcript & analysisRevenue ₹3,302 cr (+14% YoY); Operating EBITDA ₹1,083 cr (+15% YoY); EBITDA Margin 32.8%. Revenue reached ₹3,302 crores, representing a 14% YoY growth.
Read full transcript & analysisRevenue ₹3,178 cr (+11% YoY); Operating EBITDA ₹1,032 cr (+14% YoY); Adjusted EBITDA Margin 32.9%. Revenue reached ₹3,178 crores, representing an 11% YoY growth.
Read full transcript & analysisRevenue ₹2,809 cr (+3% YoY); Operating EBITDA ₹914 cr (+5% YoY); EBITDA Margin 32.5%. Revenue of ₹2,809 crores, up 3% YoY; underlying growth normalized for insulin and currency is 7%.
Read full transcript & analysisRevenue ₹2,889 cr (+9% YoY); Operating EBITDA ₹939 cr (+14% YoY); EBITDA Margin 32.5%. Revenue reached ₹2,889 crores, representing a 9% YoY growth.
Read full transcript & analysis